X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs SHASUN PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES SHASUN PHARMA VENUS REMEDIES/
SHASUN PHARMA
 
P/E (TTM) x -8.2 123.9 - View Chart
P/BV x 0.1 8.5 1.5% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 VENUS REMEDIES   SHASUN PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-17
SHASUN PHARMA
Mar-14
VENUS REMEDIES/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs14394 151.6%   
Low Rs6546 142.5%   
Sales per share (Unadj.) Rs324.2214.2 151.4%  
Earnings per share (Unadj.) Rs6.45.3 120.1%  
Cash flow per share (Unadj.) Rs40.615.8 256.5%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %01.4 0.0%  
Book value per share (Unadj.) Rs366.053.3 686.1%  
Shares outstanding (eoy) m12.3456.62 21.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.30.3 98.2%   
Avg P/E ratio x16.213.1 123.7%  
P/CF ratio (eoy) x2.64.4 58.0%  
Price / Book Value ratio x0.31.3 21.7%  
Dividend payout %018.7 0.0%   
Avg Mkt Cap Rs m1,2823,958 32.4%   
No. of employees `0000.9NA-   
Total wages/salary Rs m2512,164 11.6%   
Avg. sales/employee Rs Th4,430.1NM-  
Avg. wages/employee Rs Th278.0NM-  
Avg. net profit/employee Rs Th87.6NM-  
INCOME DATA
Net Sales Rs m4,00012,127 33.0%  
Other income Rs m23229 9.9%   
Total revenues Rs m4,02312,356 32.6%   
Gross profit Rs m7851,009 77.8%  
Depreciation Rs m422594 71.0%   
Interest Rs m344415 82.8%   
Profit before tax Rs m42230 18.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-37-73 50.9%   
Profit after tax Rs m79302 26.2%  
Gross profit margin %19.68.3 235.7%  
Effective tax rate %-87.9-31.7 277.6%   
Net profit margin %2.02.5 79.4%  
BALANCE SHEET DATA
Current assets Rs m2,6066,884 37.9%   
Current liabilities Rs m1,9808,456 23.4%   
Net working cap to sales %15.6-13.0 -120.7%  
Current ratio x1.30.8 161.7%  
Inventory Days Days12862 208.2%  
Debtors Days Days43108 40.1%  
Net fixed assets Rs m5,3534,970 107.7%   
Share capital Rs m123113 108.9%   
"Free" reserves Rs m4,3932,875 152.8%   
Net worth Rs m4,5163,020 149.5%   
Long term debt Rs m1,6181,817 89.0%   
Total assets Rs m8,29113,347 62.1%  
Interest coverage x1.11.6 72.3%   
Debt to equity ratio x0.40.6 59.5%  
Sales to assets ratio x0.50.9 53.1%   
Return on assets %5.15.4 94.9%  
Return on equity %1.810.0 17.5%  
Return on capital %6.313.3 47.2%  
Exports to sales %046.4 0.0%   
Imports to sales %18.414.2 129.2%   
Exports (fob) Rs mNA5,622 0.0%   
Imports (cif) Rs m7361,728 42.6%   
Fx inflow Rs m05,843 0.0%   
Fx outflow Rs m7362,173 33.9%   
Net fx Rs m-7363,669 -20.1%   
CASH FLOW
From Operations Rs m997398 250.8%  
From Investments Rs m-461-1,635 28.2%  
From Financial Activity Rs m-5711,309 -43.6%  
Net Cashflow Rs m-3571 -49.3%  

Share Holding

Indian Promoters % 32.9 39.2 83.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 3.6 5.0%  
FIIs % 0.6 17.6 3.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 39.6 167.7%  
Shareholders   20,121 20,750 97.0%  
Pledged promoter(s) holding % 36.4 12.3 295.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   ALKEM LABORATORIES  PLETHICO PHARMA  GLENMARK PHARMA  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2% (Quarterly Result Update)

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Aug 14, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - SANOFI INDIA COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS